In this episode, Ahmed Alderzi, CEO and co-founder of Oranda Therapeutics, shares insights into building a biotech startup focused on rare diseases, the unique approach of Oranda, and lessons learned from his 30+ years experience. Discover how they navigate the complexities of drug commercialisation and their ambitious plans for Europe and beyond.
Topics featured throughout the epidode:
- Oranda’s unique platform for late-stage medicines
- The significance of market exclusivity and generics
- Building a biotech startup in Ireland and Europe
- The importance of team and culture in startups
- Navigating regulatory and market access in pharma
- The impact of rare diseases and patient needs
- Funding and investor relations in biotech
- Operational strategies for a virtual team
- “Both industries are needed to serve patients”
- “Eighty percent of medicines in Europe are generics”
- “There are seven thousand named rare diseases”